

Clinical Trials – Arena versus CS MEDICA				
Arena Pipeline Acquisition price: 6.700,00 mio. US\$		CS MEDICA Pipeline Current Valuation: 12,4 mio. US\$¹		
Market Launch of medical treatments				
Belviq (lorcaserin) weight-loss²	June 2012		Nov. 2020	Arthritis gel
			Nov. 2020	Psoriasis gel
			May 2021	Pain Patch
			May 2021	Protective Nasal Gel
			May 2021	Wound gel
			May 2021	Nasal Spray Night
Market Launch of dermatological treatments (cosmeceuticals)				
			Aug. 2021	CBD Anti-Hair Loss Serum
			Jan. 2022	PSOR + ATOPIC Lotion
Phase 3 – Completed Clinical studies according to ICH guidelines				
			Phase 3 – Completed participants: 32	Alopecia – Hair growth efficacy – CBD Anti-Hair Loss Serum Completion date: June 2020
			Academic Clinical study – Completed participants: 6	A pharmaco-scintigraphy study of topical herbal gel (NGP-01) to evaluate its penetration into the skin on healthy male human volunteers – Psoriasis Gel Completion date: July 2021
Phase 3 – Clinical studies according to ICH guidelines				
Ulcerative Colitis – Elevate UC 52	Phase 3 participants: 200 – 1000³		Phase 3 participants: 60	Osteoarthritis – NGA-01 gel Arthritis gel Completion date: H1 2022
Ulcerative Colitis – Elevate UC 12	Phase 3 participants: 200 – 1000		Phase 3 participants: 60	Psoriasis – NGP-02 gel Psoriasis gel Completion date: H1 2022
			Phase 3 participants: 60	Osteoarthritis – NGA-01 Capsules and Arthritis gel – systemic treatment Completion date: H1 2022
			Phase 3 participants: 60	Psoriasis – NGP-02 Capsules and Psoriasis gel – systemic treatment Completion date: H1 2022
Phase 3 Planning – Clinical studies according to ICH guidelines				
Atopic Dermatitis – Advise	Phase 3 – Planning participants: 200 – 1000		Phase 3 – Planning participants: 120	NGPG-02 Capsules and Protective nasal gel
			Phase 3 – Planning participants: 120	Pain – NGPP-01 Pain Patch Expected Completion date: H1 2023
			Phase 3 – Planning participants: 120	Hay Fever – NGPG-01 Protective Nasal Gel Expected Completion date: H1 2023
			Phase 3 – Planning participants: 120	Wound treatment – NGW-01 Wound gel Expected Completion date: H1 2023
			Phase 3 – Planning participants: 240	Insomnia – Nasal Spray Night Expected Completion date: H1 2023
Phase 2 – Clinical studies according to ICH guidelines				
Ulcerative Colitis – Gladiator	Phase 2 participants: 100 – 600			

¹ Pre Money Valuation: IPO: 9,40 mio. US\$

² https://en.wikipedia.org/wiki/Arena_Pharmaceuticals

³ <https://arenaibd.com/>

Clinical Trials – Arena versus CS MEDICA				
Arena Pipeline Acquisition price: 6.700,00 mio. US\$			CS MEDICA Pipeline Current Valuation: 12,4 mio. US\$ ¹	
Eosinophilic Esophagitis – Voyage	Phase 2 participants: 100 – 600			
Irritable bowel syndrome pain – Captivate	Phase 2 participants: 100 – 600			
Alopecia Areata	Phase 2 participants: 100 – 600			
Acute heart failure	Phase 2 participants: 100 – 600			
Microvascular Obstruction	Phase 2 participants: 100 – 600			
Raynaud's phenomenon secondary to systemic sclerosis	Phase 2 participants: 100 – 600			
Academic Clinical study				
			Academic Clinical study participants: 6	A pharmaco-scintigraphy study of topical herbal gel (NGP-01) to evaluate its penetration into the skin on healthy male human volunteers, including CBD Blood test – Arthritis Gel Completion date: H1 2022
			Academic Clinical study participants: 6	A pharmaco-scintigraphy study of topical herbal Patch (NGPP-01) to evaluate its penetration into the skin on healthy male human volunteers, including CBD Blood test – Pain Patch Completion date: H1 2022
Preclinical studies completed				
Ulcerative Colitis – Elevate UC 52	Completed		Completed	Arthritis gel
Ulcerative Colitis – Elevate UC 12	Completed		Completed	Psoriasis gel
Atopic Dermatitis – Advise	Completed		Completed	Pain Patch
Ulcerative Colitis – Gladiator	Completed		Completed	Protective Nasal Gel
Eosinophilic Esophagitis – Voyage	Completed		Completed	Wound gel
Irritable bowel syndrome pain – Captivate	Completed		Completed	Nasal Spray Night
Alopecia Areata	Completed			
Acute heart failure	Completed			
Microvascular Obstruction	Completed			
Raynaud's phenomenon secondary to systemic sclerosis	Completed			
Preclinical studies				
Multiple immune & inflammatory targets	Preclinical			
Rare central nervous system Targets	Preclinical			
Preclinical studies planning:				
			Preclinical – planning	Eyelash Enhancing Serum
			Preclinical – planning	Multiple sclerosis symptoms Muscle stiffness & spasms – spasticity (medicine)
Exploratory				
Inflammatory bowel disease	Exploratory		Exploratory	CBD formula/structure and activity in human body Completion date: H2 2022
Hidradenitis Suppurativa	Exploratory			
Completed application tests in the hypoallergenic program (cosmeceuticals)				
			Application test. participants: 60 – People with Atopic Dermatitis	Evaluation of functional properties, effectiveness and tolerance of the product marked 20003214 (Psoriasis lotion) – PSOR+ATOPIC Lotion Completion date: May 2021